Non-Dystrophic Myotonia Disorder Treatment Market: By Drug Class, By Route of Administration, By Distribution Channel, and Region Forecast 2020-2031

download arrow download arrow Download Sample
settings arrow settings arrow email us

Non-Dystrophic Myotonia Disorder Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Anti-arrhythmic Class IB Drugs, Carbonic Anhydrase Inhibitors, Third-line Antimyotonic Agents, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region Forecast 2020-2031

checked icon checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Non-Dystrophic Myotonia Disorder Treatment Market size was valued at US$ 981.9 million in 2024 and is expected to reach US$ 2211.8 million by 2031, growing at a significant CAGR of 12.3% from 2025-2031. Moreover, rise in R&D for the development of newer therapeutics is expected to propel the market over the forecast years. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Global market is surging owing to approval and launch of newer therapeutics by the market players. For instance, In October 2018, Lupin received the European Medical Agency recommended granting a marketing authorisation for Namuscla (mexiletine hydrochloride) for the treatment of adult patients with non-dystrophic myotonia.

Key Developments

  • On January 28, 2025: Global pharma major Lupin Limited (Lupin) and Avas Pharmaceuticals SRL (Avas) announced the launch of Lupin’s orphan drug NaMuscla® (mexiletine) in Italy. Avas will commercialize NaMuscla® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. NaMuscla® is the first and only licensed product for this indication.
  • On Sept 27, 2024: Global pharma major, Lupin Limited (Lupin) announced that its subsidiary Lupin Atlantis Holdings SA has entered into a distribution agreement with Celnova Pharma (Celnova) for Lupin’s orphan drug NaMuscla® (mexiletine). Celnova will commercialize NaMuscla® in Argentina and Colombia, for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders.

summary download arrow Download Sample

Global Non Dystrophic Myotonia Disorder Treatment Market Summary

Study Period

2025-2031

Base Year

2024

CAGR

12.3%

Largest Market

North-America

Fastest Growing Market

Europe

Non-Dystrophic Myotonia Disorder Treatment Market Dynamics

Increase in R&D activities for the development of newer therapeutics for the non-dystrophic myotonia disorder treatment is a key factor drive the market over the forecast years. Moreover, rise in awareness about the non-dystrophic myotonia among the healthcare professionals in developed and developing countries, favorable reimbursement policies, and increase in healthcare expenditure are anticipated to propel the non-dystrophic myotonia disorder treatment market over the forecast timeframe.

Global Non Dystrophic Myotonia Disorder Treatment Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2025-2031

Market Size in 2024

US$ 981.9 million

Market Size in 2031

US$ 2211.8 million

Market CAGR

12.3%

By Drug Class

  • Anti-arrhythmic Class IB Drugs
  • Carbonic Anhydrase Inhibitors
  • Third-line Antimyotonic Agents
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The non dystrophic myotonia disorder treatment market report provides granular level information about the market size, regional market share, historic market (2020 to 2024) and forecast (2025 to 2031)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startups details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis.

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The non dystrophic myotonia disorder treatment market size was valued at US$ 981.9 million in 2024 and is expected to reach US$ 2211.8 million by 2031, growing at a significant CAGR of 12.3% from 2025-2031.

The market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Europe is the fastest-growing region for market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Non Dystrophic Myotonia Disorder Treatment Market Introduction 
2.1.Global Non Dystrophic Myotonia Disorder Treatment Market  - Taxonomy
2.2.Global Non Dystrophic Myotonia Disorder Treatment Market  - Definitions
2.2.1.Drug Class
2.2.2.Route of Administration
2.2.3.Distribution Channel
2.2.4.Region
3.Global Non Dystrophic Myotonia Disorder Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Non Dystrophic Myotonia Disorder Treatment Market Analysis, 2020 - 2024 and Forecast 2025 - 2031
4.1.  Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Non Dystrophic Myotonia Disorder Treatment Market  By Drug Class, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
5.1. Anti-arrhythmic Class IB Drugs
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Carbonic Anhydrase Inhibitors
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis
5.3. Third-line Antimyotonic Agents
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Non Dystrophic Myotonia Disorder Treatment Market  By Route of Administration, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
6.1. Oral
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Parenteral
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Non Dystrophic Myotonia Disorder Treatment Market  By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Non Dystrophic Myotonia Disorder Treatment Market  By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Non Dystrophic Myotonia Disorder Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
9.1. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Anti-arrhythmic Class IB Drugs
9.1.2.Carbonic Anhydrase Inhibitors
9.1.3.Third-line Antimyotonic Agents
9.1.4.Others
9.2.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oral
9.2.2.Parenteral
9.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Non Dystrophic Myotonia Disorder Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Anti-arrhythmic Class IB Drugs
10.1.2.Carbonic Anhydrase Inhibitors
10.1.3.Third-line Antimyotonic Agents
10.1.4.Others
10.2.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oral
10.2.2.Parenteral
10.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Non Dystrophic Myotonia Disorder Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Anti-arrhythmic Class IB Drugs
11.1.2.Carbonic Anhydrase Inhibitors
11.1.3.Third-line Antimyotonic Agents
11.1.4.Others
11.2.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oral
11.2.2.Parenteral
11.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Non Dystrophic Myotonia Disorder Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Anti-arrhythmic Class IB Drugs
12.1.2.Carbonic Anhydrase Inhibitors
12.1.3.Third-line Antimyotonic Agents
12.1.4.Others
12.2.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oral
12.2.2.Parenteral
12.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Non Dystrophic Myotonia Disorder Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Anti-arrhythmic Class IB Drugs
13.1.2.Carbonic Anhydrase Inhibitors
13.1.3.Third-line Antimyotonic Agents
13.1.4.Others
13.2.  Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oral
13.2.2.Parenteral
13.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Novartis AG
14.2.2.Johnson and Johnson Services, Inc.
14.2.3.GlaxoSmithKline plc
14.2.4.Allergan plc
14.2.5.Sanofi S.A.
14.2.6.Lupin Ltd.
14.2.7.Pfizer, Inc.
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Novartis AG
  • Johnson and Johnson Services, Inc.
  • GlaxoSmithKline plc
  • Allergan plc
  • Sanofi S.A.
  • Lupin Ltd.
  • Pfizer, Inc.

Related Industry Reports

CDK6 Inhibitors Market

Global Neurological Disorder Diagnostics Market

Histone Deacetylase Inhibitors Market

Global Acute Conjunctivitis Treatment Market